QT Imaging Launches QTviewer 2.8 to Enhance Clinical Efficiency and Diagnostic Accuracy
QTviewer stores and displays the QTscan™ images generated by the Company's U.S. FDA-cleared QTI Breast Acoustic CT™ scanner, the first non-invasive breast imaging technology that provides a true 3D image of the breast anatomy without compression, contrast administration, or harmful ionizing radiation — setting a new standard for safe and repeatable monitoring.
Key features of QTviewer 2.8 include:
Effortless, Stateless DICOM (Digital Imaging and Communications in Medicine) Viewing: QTviewer 2.8 enables instant access to QTscan studies without a preconfigured database — ideal for remote reads, portable drives, or low-resource environments. This also supports direct PACS (Picture Archiving and Communication System) integration where available.
Real-Time Lesion Doubling Time Analysis: Integrated tool allows clinicians to assess lesion growth within the standard reading workflow — enhancing monitoring of disease progression or treatment response. Unlike conventional methods, QTI's technology enables fully quantitative, volumetric analysis without the need for contrast agents or ionizing radiation.
New RGB Visualization Modes: Enables interpretation of both anatomical structures and quantitative data, supporting diagnostic and research use cases alike. The RGB mode incorporates speed of sound mapping, providing additional visual representation of tissue composition and imaging findings — an essential capability for advancing our research into lesion characterization and AI-driven classification.
Advanced Multi-Series Comparison: Radiologists can now view multiple series from the same study in parallel windows, improving anatomical and temporal comparisons.
Optimized Viewport Layouts for Radiology Workstations: Vertical orientation and multi-monitor support improve ergonomics and diagnostic clarity for stackable and long-axis views.
Secure License Management for Enterprise Use: PC-based license key verification ensures secure, compliant deployment across hospital and academic systems.
Improved Stability & Usability: Backend upgrades streamline loading, enhance compatibility, and support quick launches from file associations or command line; and
Reinforced Diagnostic Workflow: QTviewer 2.8 provides automatic recognition of image types, such as speed-of-sound, attenuation, and reflection, ensuring seamless workflow and consistent interpretation.
'This is an exciting time for our team as we enter into a period of anticipated rapid growth, driven by continuous innovation like our recent release of image reconstruction software, version 4.4.0, which delivers a substantial reduction in the QTscan™ image processing time, improving user throughput and overall efficiency, and this enhanced generation of QTviewer,' said QTI's Chief Science Officer, Dr. Bilal Malik. 'By providing radiologists and clinical partners with a growing portfolio of enabling, intuitive support tools, QTI aims to expand access to medical imaging while ensuring superior patient experience and improving health outcomes.'
Transforming QTI into a precision imaging AI company is a key pillar of the Company's growth strategy. To that end, beyond today's announcement, the QTI team continues to innovate by not only developing proprietary AI/ML tools designed to accelerate image processing and reduce scanning time, but also conducting AI/ML projects which will be viewed/integrated in the QTviewer in the future.
About QT Imaging Holdings, Inc.
QT Imaging Holdings, Inc. is a public (OTCQB: QTIH) medical device company engaged in research, development, and commercialization of innovative body imaging systems using low frequency sound waves. QT Imaging Holdings, Inc. strives to improve global health outcomes. Its strategy is predicated upon the fact that medical imaging is critical to the detection, diagnosis, and treatment of disease and that it should be safe, affordable, accessible, and centered on the patient's experience. For more information on QT Imaging Holdings, Inc., please visit the company's website at www.qtimaging.com.
Breast Acoustic CT™ is a trademark of an affiliate of QT Imaging Holdings, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements contain words such as 'will,' and 'expect,' or the negative thereof or comparable terminology, and include (without limitation) statements regarding the presentation and performance of QTviewer and the QT Imaging Breast Acoustic CT imaging technology, plans for QT Imaging Holdings, including transforming it into a precision imaging AI company, new product development and introduction, and product sales growth and projected revenues. Forward-looking statements involve certain risks and uncertainties, and actual results may differ materially from those discussed in any such statement. These risks include, but are not limited to: research results from the use of the QT Imaging Breast Acoustic CT Scanner, clinical studies, the ability of QT Imaging Holdings to sell and deploy the QT Imaging Breast Acoustic CT Scanner, the ability to extend product offerings into new areas or products, the ability to commercialize technology, unexpected occurrences that deter the full documentation and 'bring to market' plan for products, trends and fluctuations in the industry, changes in demand and purchasing volume of customers, unpredictability of suppliers, the ability to attract and retain qualified personnel and the ability to move product sales to production levels. Additional factors that could cause actual results to differ are discussed under the heading 'Risk Factors' and in other sections of QT Imaging Holding's filings with the SEC, and in its other current and periodic reports filed or furnished from time to time with the SEC. All forward-looking statements in this press release are made as of the date hereof, based on information available to QT Imaging Holdings as of the date hereof, and QT Imaging Holdings assumes no obligation to update any forward-looking statement.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
5 hours ago
- Business Upturn
SmartVascular Dx™ Test Elevates Vascular Risk Detection in the Northeast & Partnership with MOMS
IRVINE, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) — MorningStar Laboratories, LLC., ('MSL' or 'the Company'), a leading developer of precision diagnostic tests addressing unmet clinical needs, is excited to announce that its SmartVascular Dx™ (SVDx) test, formerly known as the PULS™ Cardiac Test, is now more accessible than ever for patients in the northeastern United States. We are proud to share that we have been included in the Medicare fee schedule, allowing us to offer national Medicare coverage along with our new partnerships with CareSource and HealthPartners. The SmartVascular Dx test provides a significant clinical advantage by accurately detecting vascular inflammation, a crucial factor in assessing cardiovascular risk. In a healthcare landscape increasingly focused on preventive strategies, this test supports early intervention, aligning seamlessly with the commitment to proactive healthcare in the region. We encourage physicians in the northeastern United States to seize this opportunity to offer the SVDx test to their patients. By identifying vascular risks earlier, healthcare providers can implement timely interventions, ultimately saving lives and improving health outcomes. Furthermore, we are excited to announce our partnership with My One Medical Source® (MOMS), and its network of MAPs: Medical Access Points/Providers™, which will facilitate specimen collection opportunities for MorningStar Laboratories' patients across the country. As the 'Connection for the Collection™,' MOMS enhances access to testing by bridging labs like ours with the skilled personnel needed for specimen collection. For more information and to learn how to integrate the SmartVascular Dx test into your practice, please reach out MorningStar Laboratories at 866.299.8998. Join us in our mission to enhance vascular care and improve the health of our communities. About MorningStar Laboratories MorningStar Laboratories ('MSL') is a specialty diagnostics development clinical laboratory company that develops, performs, and distributes unique medical tests combining science, technology, and proprietary analytics which aim to detect high-risk diseases with significant unmet medical needs. MSL's laboratory information systems use data from multiple sources, including proteomics, genetics, metabolic, biochemistry, phenotype, imaging, and a patented algorithm to address the most challenging clinical problems related to endothelial and vascular inflammatory issues. Morningstar Laboratories, a subsidiary of Smart Health Diagnostics Company, is a CLIA-Certified and CAP Accredited laboratory offering comprehensive and customized services in accordance with Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP) regulations and ISO 15189 standards. To learn more, visit MorningStar Laboratories at Facebook, X (formerly Twitter), and LinkedIn. About My One Medical Source® (MOMs) My One Medical Source® (MOMS) is a SaaS platform connecting labs and other clients with the skilled labor required to perform specimen collections. The MAP: Medical Access Point/Provider™ Network is comprised of both brick-and-mortar draw sites as well as mobile phlebotomy options in all 50 states and Puerto Rico, which serve as collection solutions for the Labs/Clients on the MOMS platform. To learn more, visit Forward-Looking Statements Forward-looking statements in this press release are based on our future expectations, plans prospects, and assumptions regarding matters that are not historical facts, may constitute 'forward-looking statements' within the meaning of The Private Securities Litigation Reform Act of 1995. The words 'termed,' 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would' and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. Therefore, we caution you against relying on any of these forward-looking statements. They are neither statements of historical fact nor guarantees or assurances of future performance. Any forward-looking statement made by us in this document speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as may be required by law. Media Contact [email protected] 866.299.8998 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Business Wire
6 hours ago
- Business Wire
Align Technology President and CEO Joe Hogan Personally Purchases $1 Million of Align's Common Stock
TEMPE, Ariz.--(BUSINESS WIRE)--Align Technology, Inc. ('Align') (Nasdaq: ALGN) a leading global medical device company that designs, manufactures, and sells the Invisalign ® System of clear aligners, iTero™ intraoral scanners, and exocad™ CAD/CAM software for digital orthodontics and restorative dentistry, today announced that Joe Hogan, Align Technology president and CEO, has personally purchased approximately $1 million of Align's common stock. Since his last sale of Align common stock in 2021, Mr. Hogan has purchased approximately $8 million of Align common stock 1. 'This purchase reflects my continuing confidence in the long-term value of Align and our commitment to increasing shareholder value by balancing investments to drive growth and continuing to invest with discipline in the areas that will define our future,' said Joe Hogan, president and CEO. 'We are excited about our next-generation technologies and treatment platforms that meet today's patient expectations for fast, effective, and personalized treatment while also providing value and growth opportunities for our doctor customers. We believe that these innovations are not only improving outcomes in Invisalign practices but also expanding our addressable market and strengthening our competitive differentiation.' Continued Hogan, 'While we believe that the macroeconomic uncertainty will likely persist into the near future, we are confident in our ability to adapt and lead. Our long-term strategic initiatives and opportunities remain intact, as does our commitment to focused execution on transforming treatment for doctors and patients.' 1 Valued based on the purchase price of Align common stock at the time of each purchase. About Align Technology Align Technology designs and manufactures the Invisalign ® System, the most advanced clear aligner system in the world, iTero™ intraoral scanners and services, and exocad™ CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 286.4 thousand doctor customers and are key to accessing Align's 600 million consumer market opportunity worldwide. Over the past 28 years, Align has helped doctors treat over 20.8 million patients with the Invisalign System and is driving the evolution in digital dentistry through the Align™ Digital Platform, our integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Visit for more information. For additional information about the Invisalign System or to find an Invisalign doctor in your area, please visit For additional information about the iTero digital scanning system, please visit For additional information about exocad dental CAD/CAM offerings and a list of exocad reseller partners, please visit Invisalign, iTero, exocad, Align, Align Digital Platform, and iTero Lumina are trademarks of Align Technology, Inc.
Newsweek
8 hours ago
- Newsweek
Freeze Dried Fruit Recall Sparks Warning to Customers Across the US
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Doehler Dry Ingredient Solutions, LLC is recalling the Member's Mark brand of freeze-dried fruit variety packs due to fears the product is contaminated with Listeria monocytogenes. Newsweek attempted to reach the company via phone on Friday for comment but could not leave a voicemail. Why It Matters Numerous recalls have been initiated this year due to the potential for damaged products, foodborne illness, contamination and undeclared food allergens. Millions of Americans experience food sensitivities or allergies every year. According to the U.S. Food and Drug Administration (FDA), the nine "major" food allergens in the U.S. are eggs, milk, fish, wheat, soybeans, Crustacean shellfish, sesame, tree nuts and peanuts. Listeria monocytogenes is a bacterium that poses significant health risks, particularly to pregnant women, newborns, older adults, and individuals with weakened immune systems, according to the FDA. What To Know In the alert, the FDA notes that the products were distributed from July 1, 2025, until July 25, 2025, at Sam's Club retail locations. The states and territories impacted by this recall are: Alabama Arizona California Colorado Connecticut Delaware Florida Georgia Hawaii Iowa Indiana Illinois Idaho Kansas Louisiana Maryland Maine Mississippi Minnesota Missouri Michigan Montana North Carolina North Dakota Nebraska New Hampshire New Jersey New Mexico Nevada New York Ohio Oklahoma Pennsylvania South Carolina South Dakota Tennessee Texas Utah Virginia Wisconsin West Virginia Wyoming Puerto Rico The Member's Mark Freeze Dried Fruit Variety Pack's being recalled are in 15 count boxes with a UPC number of 1 93968 50900 2, the FDA said. The agency added that no illnesses have been reported as of Thursday. The alert has a chart listing the recalled products with corresponding lot code numbers and use by dates for consumers to cross reference. The problem was discovered via "internal testing," the FDA says. A 15-count package of freeze dried fruit variety packs can be seen in connection to a recall on July 31, 2025. (Photo by the U.S. Food and Drug Administration) A 15-count package of freeze dried fruit variety packs can be seen in connection to a recall on July 31, 2025. (Photo by the U.S. Food and Drug Administration) What People Are Saying The FDA on its website in part about the incubation period for Listeria infection: "There can be a substantial delay between the time of ingestion of contaminated food and the onset of serious symptoms. The average time from exposure to illness is approximately 30 days, but symptoms can appear as long as 90 days after exposure. It is important for consumers to know that the infection can occur as much as 90 days later, so that they can seek appropriate treatment if they have symptoms of Listeria infection." What Happens Next? Consumers are advised to contact Doehler Dry Ingredient Solutions, LLC's Customer Service via phone at (770) 387-0451 on weekdays from 8 a.m. to 5 p.m. ET with any additional questions, the FDA says. Health authorities continue to emphasize the importance of proper food storage and handling, particularly for ready-to-eat items. The FDA advises consumers to refrigerate perishable foods at and under 40°F, discard recalled products and properly sanitize surfaces that may have contacted suspected contaminated items to prevent the risk of cross-contamination.
